Trial Profile
A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M™ Adjuvant in Children 6 Months to < 12 Years of Age
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 29 Jan 2024
Price :
$35
*
At a glance
- Drugs NVX CoV 2373 (Primary) ; Matrix-M1 Adjuvant
- Indications COVID 2019 infections
- Focus Adverse reactions
- Acronyms hummingbird
- Sponsors Novavax
- 22 Jan 2024 Status changed from recruiting to active, no longer recruiting.
- 11 Oct 2023 According to Novavax media release, data from this trial will be presented at the World Vaccine Congress Europe 2023.
- 04 Aug 2022 According to Novavax media release, Initial results from this study are expected in Q1 2023.